Sirolimus to prevent recurrent squamous cell skin cancer, The Visual Abstract

swapnil hiremath

November 26, 2018

By NSMC graduate, Angel Ortiz

Tweet Feed

Thank you for joining the conversation about the MENTOR study and making #NephJC chat great! Don’t forget we have o… https://t.co/ykE3qAJwBF
about 6 days ago
Would you like to have some #NephJC swag? Order it here https://t.co/eTUrZY27Qo
about 6 days ago
Thanks @jenniejlin for amazing summary and @Stones__ for the VA #NephJC
about 6 days ago
If you haven’t already, please sign up for our weekly newsletter https://t.co/5aumn8qL85 #NephJC https://t.co/rbyUtMrboS
about 6 days ago
Final thoughts or comments? #NephJC
about 6 days ago
Which MN patients of yours will you prescribe RTX? #nephjc
about 6 days ago
T3: We will be winding down in a few minutes. What are your take home points? #NephJC
about 6 days ago
What would be your RCT design for treatment of MN ? #NephJC
about 6 days ago
T3: Rituximab is not a perfect therapy by any means. For the scientists and innovators in the group, how would you… https://t.co/gKpE0hqnwM
about 6 days ago
T3: What are some strengths and limitations of the study? #NephJC
about 6 days ago
T3: We asked you before the chat what your pre-MENTOR PMN treatment approach was. Will the MENTOR study change the… https://t.co/IOsBmeQAVe
about 6 days ago
T3: Now let’s move on to Discussion. #NephJC
about 6 days ago
T2: Any thoughts or comments on the quality of life assessment and results? #NephJC
about 6 days ago
Asian population is not represented in this trial, they could have had an arm of Cyclo vs RTX with indian pts :) what say? #NephJC
about 6 days ago
T2: No statistically significant differences in adverse events, although there were certainly qualitative differenc… https://t.co/nHOjzsIVAL
about 6 days ago
T2: And what about treatment failure? Higher (80%) in cyclosporine group vs rituximab group (40%), as seen in Figur… https://t.co/jlF1aUioKK
about 6 days ago
T2: What are your thoughts on using anti-PLA2R to track disease activity and as an outcome for PMN trials? #NephJC
about 6 days ago
T2: Figure S10 shows what happens to anti-PLA2R levels over time in the two treatment arms. The log scale makes eve… https://t.co/z2vIljqyLM
about 6 days ago
T2: Figure S8 shows what happens to proteinuria over time in the two treatment arms. Note the y-axis is on a log sc… https://t.co/2N54NrM19M
about 6 days ago
T2 Compared to cyclosporine, Rituximab was noninferior at 12 months and superior at 24 months in achieving the comp… https://t.co/YiEEYzzDJu
about 6 days ago